Board resolution - Buyback
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty 100 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Lifesciences Limited's Board has approved a buyback of up to 95,65,217 equity shares (approximately 0.95% of total paid-up capital) at INR 1,150 per share. The maximum buyback amount is INR 1,100 crore, representing 5.16% and 3.84% of standalone and consolidated free reserves respectively as of March 31, 2026. The buyback will be conducted via tender offer through NSE (designated stock exchange) on a proportionate basis, with 15% reserved for small shareholders. The record date is May 29, 2026, and the buyback must be completed within one year from the board meeting date. ICICI Securities is appointed as manager and buying broker, with MUFG Intime as the registrar. Promoter and promoter group are also eligible to participate.
The buyback offers shareholders a chance to exit at INR 1,150 per share, representing a return of capital. With the company confirming no grounds for insolvency and adequate financial resources, this is positive for shareholders seeking liquidity at the offer price.